Showing results (1-10 of 449) with videos related to
Sort By:
Pageof 45
Arthritis Research & Therapy|June 26, 2013
Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cellsAdrian J Gilbane, Christopher P Denton, Alan M HolmesThe American Journal of Pathology|May 10, 2015
Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial HypertensionRobert B Good, Adrian J Gilbane, Sarah L Trinder, et al.American Journal of Respiratory and Critical Care Medicine|January 22, 2015
Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-β-dependent mouse model of pulmonary hypertension and in systemic sclerosisAdrian J Gilbane, Emma Derrett-Smith, Sarah L Trinder, et al.Arthritis and Rheumatism|July 11, 2013
Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertensionEmma C Derrett-Smith, Audrey Dooley, Adrian J Gilbane, et al.Journal of Cell Communication and Signaling|July 20, 2011
Elevated CCN2 expression in scleroderma: a putative role for the TGFβ accessory receptors TGFβRIII and endoglinAlan M Holmes, Markella Ponticos, Xu Shi-Wen, et al.Arthritis & Rheumatology (Hoboken, N.J.)|October 11, 2014
Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosisMarkella Ponticos, Ioannis Papaioannou, Shiwen Xu, et al.Clinical and Experimental Rheumatology|October 13, 2015
Systemic sclerosis: from pathogenesis to targeted therapyChristopher P DentonClinical Medicine (London, England)|February 3, 2016
Advances in pathogenesis and treatment of systemic sclerosisChristopher P DentonClinical Medicine (London, England)|December 5, 2015
Advances in pathogenesis and treatment of systemic sclerosisChristopher P DentonArthritis Research & Therapy|September 15, 2007
Therapeutic targets in systemic sclerosisChristopher P DentonPageof 45